Company / Accounts Receivable
Haemonetics Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$202.7M
FY2025
5-year range
$127.6M / $206.6M
FY2021-FY2025
Trend
-1.9%
vs FY2024
Sector context
#73 of 143
Health Care
What the data says
At $203M, Haemonetics's accounts receivable ranks #73 of 143 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $128M in FY2021 to $207M in FY2024.
Based on SEC 10-K filings.
$203M in FY2025 with a 5-year CAGR of +4.2%.
Improved from $179M to $203M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.3%
- 5-Year CAGR
- +4.2%
- 10-Year CAGR
- -
Sector benchmark
#73 of 143 in Health CareTop 51% of 143This company $202.7M Sector average $1.3B
▼
-84.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.2%, indicating consistent growth.
- In FY2025, accounts receivable decreased 1.9% year-over-year.
- Ranks #73 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $202.7M | -1.9% |
| FY2024 | $206.6M | +15.3% |
| FY2023 | $179.1M | +12.4% |
| FY2022 | $159.4M | +24.9% |
| FY2021 | $127.6M | -22.8% |
| FY2020 | $165.2M | -10.7% |
| FY2019 | $185.0M | +22.4% |
| FY2018 | $151.2M | -1.0% |
| FY2017 | $152.7M | -2.8% |
| FY2016 | $157.1M | +7.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026